New Malvern Publication Shows Zetasizer APS Analyses Sticky Proteins with no Cross-Contamination

A new application note published on the Malvern Instruments website demonstrates the absence of any cross-contamination when using the company’s Zetasizer APS (Auto Plate Sampler) to analyse known ‘sticky’ proteins. The Zetasizer APS dynamic light scattering (DLS) system enables the automated measurement of multiple samples and has wide application in the rapid screening of proteins. The risk of cross-contamination is a concern to many people when considering automated analysis in a multiwell format and the experiment was designed to thoroughly test the instrument’s capabilities. The application note can be downloaded at www.malvern.com/dlsautomation.
Setup and operation of the Zetasizer APS is straightforward and its stringent cleaning protocols are designed to ensure that no cross-contamination occurs. The work described in the new application note used familiar protein samples to demonstrate the lack of detectable cross-contamination. Samples included insulin, in both “monomeric” (the insulin hexamer) and “oligomeric” forms, and Abeta, the amyloid beta peptide known for its stickiness and tendency to adhere to plastic. The Abeta sample was present in two forms, fibrillar and oligomeric.
The order in which samples were loaded onto the system was chosen so as to maximize the risk of cross-contamination. The oligomeric insulin was dispensed first using a standard pipette, followed by the small and pure insulin, and then the larger polydisperse Abeta samples. Since large protein aggregates scatter much more light than small pure protein samples, if cross-contamination were to occur the polydisperse Abeta sample would be detected within the small homogenous protein sample. The results show that after running multiple tests, there was no detectable cross-contamination.
The Zetasizer APS delivers the same high sensitivity, high specification DLS measurements as other systems in Malvern’s established Zetasizer family. The automated processing of samples in multiwell plates enables the generation of high quality DLS data with no user intervention, a major benefit in maximizing productivity. The system’s highly practical data display capability allows easy retrieval of results of interest, eliminating the need to manually scan through all measurements. In addition, the Zetasizer APS plate navigator feature acts as a data mapping tool, for rapid screening of results to retrieve the information of most interest and subsequent in-depth investigation of selected data sets.
The separate temperature controls of the plate holder and the measurement cell allow the Zetasizer APS to maintain the protein samples in optimal condition until measurement. In addition, thermal trend measurements between 2 °C to 90 °C with 0.1 °C degree precision can be defined. The plate scheduler allows the user to graphically set up size and thermal trend measurements of various samples from the same plate using a variety of different SOPs.
Related News
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease. -
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries. -
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance